Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Jiandong Huo, Yuguang Zhao, Jingshan Ren and 22 more

Cell Host & Microbe · 2020 · CC BY

doi:10.1016/j.chom.2020.06.010

Abstract

There are as yet no licensed therapeutics for the COVID-19 pandemic. The causal coronavirus (SARS-CoV-2) binds host cells via a trimeric spike whose receptor binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformational changes that drive membrane fusion. We find that the monoclonal antibody CR3022 binds the RBD tightly, neutralizing SARS-CoV-2, and report the crystal structure at 2.4 Å of the Fab/RBD complex. Some crystals are suitable for screening for entry-blocking inhibitors. The highly conserved, structure-stabilizing CR3022 epitope is inaccessible in the prefusion spike, suggesting that CR3022 binding facilitates conversion to the fusion-incompetent post-fusion state. Cryogenic electron microscopy (cryo-EM) analysis confirms that incubation of spike with CR3022 Fab leads to destruction of the prefusion trimer. Presentation of this cryptic epitope in an RBD-based vaccine might advantageously focus immune responses. Binders at this epitope could be useful therapeutically, possibly in synergy with an antibody that blocks receptor attachment.

References 60

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R · 2006
No notice
12.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
Acaricide, Fungicide and Drug Interactions in Honey Bees (Apis mellifera) · 2013
No notice
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus · 2012
Corrected
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
REFMAC 5 for the refinement of macromolecular crystal structures · 2011
No notice
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006
No notice
26.
Phaser crystallographic software · 2007
No notice
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
31.
GISAID: Global initiative on sharing all influenza data – from vision to reality · 2017
No notice
32.
Antibody therapies for the prevention and treatment of viral infections · 2017
No notice
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
DIALS : implementation and evaluation of a new integration package · 2018
No notice
35.
Three-dimensional Epigenome Statistical Model: Genome-wide Chromatin Looping Prediction · 2018
No notice
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
37.
Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 · 2018
No notice
38.
Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis · 2018
Corrected
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
41.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
42.
Gctf: Real-time CTF determination and correction · 2016
No notice
43.
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix · 2019
No notice
44.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
45.
Development of therapeutic antibodies for the treatment of diseases · 2020
No notice
46.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
47.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
48.
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody · 2020
No notice
49.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
50.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
51.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020
No notice
52.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
53.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
54.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
55.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
56.
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients · 2020
No notice
57.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
58.
A human monoclonal antibody blocking SARS-CoV-2 infection · 2020
Corrected
59.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
60.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 11

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses · 2022
Not checked
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines · 2022
No notice
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
No notice
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
No notice
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study · 2021
No notice
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class · 2021
Not checked
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates · 2021
No notice
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape · 2021
No notice
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 · 2021
No notice
Antibodies and Vaccines Target RBD of SARS-CoV-2 · 2021
No notice
Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be · 2020
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.